

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,

Petitioner,

v.

NOVO NORDISK A/S,

Patent Owner.

Case No. IPR2023-00724
U.S. Patent No. 10,335,462

**DECLARATION OF DAVID L. ANSTAETT
IN SUPPORT OF MOTION FOR *PRO HAC VICE* ADMISSION OF
DAVID L. ANSTAETT**

I, David L. Anstaett, declare as follows:

1. I am a partner in the patent litigation group at Perkins Coie LLP.
2. I am a member in good standing of the Bar of the State of Wisconsin and the Commonwealth of Virginia. I am also admitted to practice before the United States Supreme Court, United States Courts of Appeals for the Fourth Circuit, D.C. Circuit, and the Federal Circuit. I am admitted to practice before the United States District Courts for D.C. and Wisconsin.
3. My Bar membership numbers are VA 46614 and WI 1037884.
4. I have been practicing law for 22 years, including litigating patent cases, specifically focused on pharmaceutical and life science patent cases, for approximately 14 years.
5. More generally, I have represented the Petitioner and/or its various related entities in litigating significant pharmaceutical patent cases, such as the following patent cases:
 - *Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc.*, No. 09-08824 (U.S. District Court for the Southern District of New York);
 - *Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc.*, No. 10-7246 (U.S. District Court for the Southern District of New York);

- *Teva Pharmaceuticals USA Inc. v. Sandoz Inc.*, Nos. 12-1567, 12-1568, 12-1569, 12-1570 (U.S. Court of Appeals for the Federal Circuit);
- *AstraZeneca AB v. Mylan Laboratories Ltd.*, No. 12-cv-01378 (U.S. District Court for the District of New Jersey);
- *Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc.*, No. 14-cv-01278 (U.S. District Court for the District of Delaware);
- *In re Copaxone 40 mg Cases*, No. 14-1171 (U.S. District Court for the District of Delaware);
- *Hospira, Inc. v. Burwell*, No. 14-2662 (U.S. District Court for the District of Maryland);
- *BTG Int'l Ltd. v. Actavis Labs. FL, Inc.*, No. 15-cv-05909 (U.S. District Court for the District of New Jersey);
- *The Medicines Co. v. Mylan Inc.*, No. 15-1113, 15-1151, 15-1181 (U.S. Court of Appeals for the Federal Circuit);
- *AstraZeneca AB v. Mylan Laboratories Ltd.*, No. 15-1889 (U.S. Court of Appeals for the Federal Circuit);
- *AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc.*, No. 15-183 (U.S. District Court for the Northern District of West Virginia);

- *Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc.*, No. 17-00007 (U.S. District Court for the Northern District of West Virginia);
- *Biogen Int'l GmbH v. Mylan Pharmaceuticals Inc.*, No. 17-00116 (U.S. District Court for the Northern District of West Virginia);
- *Teva Pharmaceuticals USA Inc. v. Mylan Pharmaceuticals Inc.*, No. 17-249 (U.S. District Court for the District of Delaware);
- *Teva Pharmaceuticals USA Inc. v. Sandoz Inc.*, No. 17-cv-1575 (U.S. Court of Appeals for the Federal Circuit);
- *Yeda Research & Development Co. v. Mylan Pharmaceuticals Inc.*, Nos. 17-1594, 17-1595, 17-1596 (U.S. Court of Appeals for the Federal Circuit);
- *AstraZeneca AB v. Mylan Laboratories Ltd.*, No. 18-193 (U.S. District Court for the Northern District of West Virginia);
- *AstraZeneca AB v. Mylan Pharmaceuticals Inc.*, No. 18-01562 (U.S. District Court for the District of Delaware);
- *AstraZeneca AB v. Mylan Pharmaceuticals Inc.*, No. 19-00203 (U.S. District Court for the Northern District of West Virginia);
- *BTG Int'l Ltd. v. Amneal Pharmaceuticals LLC*, No. 19-1147 (U.S. Court of Appeals for the Federal Circuit);

- *Teva Pharmaceuticals USA Inc. v. FDA*, No. 20-808 (U.S. District Court for the District of Columbia);
- *Mylan Pharmaceuticals Inc. v. Biogen MA Inc.*, No. 20-1673 (U.S. Court of Appeals for the Federal Circuit);
- *Biogen Int'l GmbH v. Mylan Pharmaceuticals Inc.*, No. 20-1933 (U.S. Court of Appeals for the Federal Circuit);
- *Biogen Int'l GmbH v. Mylan Pharmaceuticals Inc.*, No. 21-1567 (U.S. Supreme Court);
- *AstraZeneca AB v. Mylan Pharmaceuticals Inc.*, No. 21-1729 (U.S. Court of Appeals for the Federal Circuit);
- *AstraZeneca AB v. Mylan Pharmaceuticals Inc.*, No. 22-35 (U.S. District Court for the Northern District of West Virginia);
- *Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Ltd.*, No. 22-464 (U.S. District Court for the District of Delaware);
- *Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc.*, No. 22-1040 (U.S. District Court for the District of Delaware);
- *In re: Ozempic (Semaglutide) Patent Litigation*, No. 22-MD-3038 (U.S. District Court for the District of Delaware);

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.